Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1
Small cell lung cancer (SCLC) is an aggressive malignancy distinct from non–small cell lung
cancer (NSCLC) in its metastatic potential and treatment response. Using an integrative …
cancer (NSCLC) in its metastatic potential and treatment response. Using an integrative …
[HTML][HTML] Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung …
Small cell lung cancer (SCLC) is one of the most aggressive forms of cancer, with a 5-year
survival< 7%. A major barrier to progress is the absence of predictive biomarkers for …
survival< 7%. A major barrier to progress is the absence of predictive biomarkers for …
Unravelling the biology of SCLC: implications for therapy
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer
T Sato, A Kaneda, S Tsuji, T Isagawa, S Yamamoto… - Scientific reports, 2013 - nature.com
Small cell lung cancer (SCLC) is a subtype of lung cancer with poor prognosis. Expression
array analysis of 23 SCLC cases and 42 normal tissues revealed that EZH2 and other PRC2 …
array analysis of 23 SCLC cases and 42 normal tissues revealed that EZH2 and other PRC2 …
[HTML][HTML] Targeted therapies and biomarkers in small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid growth,
early metastasis, and acquired therapeutic resistance. A majority of patients with SCLC have …
early metastasis, and acquired therapeutic resistance. A majority of patients with SCLC have …
Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer
Small cell lung cancer (SCLC) is a highly aggressive lung neoplasm with extremely poor
clinical outcomes and no approved targeted treatments. To elucidate the mechanisms …
clinical outcomes and no approved targeted treatments. To elucidate the mechanisms …
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
Small cell lung cancer (SCLC) is a particular subtype of lung cancer with high mortality.
Recent advances in understanding SCLC genomics and breakthroughs of immunotherapy …
Recent advances in understanding SCLC genomics and breakthroughs of immunotherapy …
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Purpose: PARP inhibitors (PARPi) are a novel class of small molecule therapeutics for small
cell lung cancer (SCLC). Identification of predictors of response would advance our …
cell lung cancer (SCLC). Identification of predictors of response would advance our …
Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer
M Taniwaki, Y Daigo, N Ishikawa… - International …, 2006 - spandidos-publications.com
To characterize the molecular mechanisms involved in the carcinogenesis and progression
of small-cell lung cancer (SCLC) and identify molecules to be applied as novel diagnostic …
of small-cell lung cancer (SCLC) and identify molecules to be applied as novel diagnostic …
Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer
Lung cancer is the leading cause of cancer-related mortality in the world, with small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC) comprising the two major cell types …
cancer (SCLC) and non-small cell lung cancer (NSCLC) comprising the two major cell types …